On this page
mrd
Explore "mrd" with insightful episodes like "Mount Ridley Mines Limited (ASX:MRD) - The Mount Ridley REE Project - The Next Stage.", "Mount Ridley Mines Limited (ASX:MRD) - A Consolidating Rare Earth Project in Western Australia.", "Mount Ridley Mines Limited (ASX:MRD) - Rare Earths in the Esperance Region, Western Australia.", "Mount Ridley Mines Limited (ASX:MRD) - A Rare Earth Story." and "Is MRD an important prognostic factor for predicting relapse in AML?" from podcasts like ""Coffee with Samso", "Coffee with Samso", "Coffee with Samso", "Coffee with Samso" and "The EMJ Podcast: Insights For Healthcare Professionals"" and more!
Episodes (26)
Mount Ridley Mines Limited (ASX:MRD) - A Consolidating Rare Earth Project in Western Australia.
Mount Ridley Mines Limited (ASX:MRD) - Rare Earths in the Esperance Region, Western Australia.
Mount Ridley Mines Limited (ASX:MRD) - A Rare Earth Story.
Is MRD an important prognostic factor for predicting relapse in AML?
This podcast explores with guest speaker Dr Richard Dilon the potential prognostic value of measurable residual disease (MRD) determination in the treatment and risk assessment of patients with acute myeloid leukaemia (AML).
This podcast is supported by Jazz Pharmaceuticals, who have had input into the topic and final editorial review. The views expressed in this podcast are those of the individual speakers and do not necessarily reflect the views of Jazz Pharmaceuticals.
Ruolo della MRD nel trattamento del mieloma multiplo
Multiple Shades of Myeloma
Negli ultimi anni il panorama di trattamento del mieloma multiplo è stato rivoluzionato dall’avvento di numerose opzioni terapeutiche che hanno significativamente migliorato la qualità e l’attesa di vita dei pazienti. Dalle parole degli specialisti un excursus tra nuovi protocolli, immunoterapie e biomarcatori prognostici.
Seguici sui nostri social
Insufficienza renale nel mieloma multiplo, a che punto siamo?
Multiple Shades of Myeloma
Negli ultimi anni il panorama di trattamento del mieloma multiplo è stato rivoluzionato dall’avvento di numerose opzioni terapeutiche che hanno significativamente migliorato la qualità e l’attesa di vita dei pazienti. Dalle parole degli specialisti un excursus tra nuovi protocolli, immunoterapie e biomarcatori prognostici.
Seguici sui nostri social
MR D JOE DOMBROWSKI Joins BENNY BASH on KBPI
The Forgivably Canadian Dr. Joe Mikhael, Myeloma, and Justin Trudeau Clickbait
On today’s show, Dr. Joseph Mikhael, Professor of Applied Cancer Research at the TGen institute for City of Hope AND the Chief Medical Officer of the International Myeloma Foundation, an incredible nonprofit advocacy and research organization that I’ve been proud to call a partner for many many years. They’re a great group. Joe is one of the most highly coveted and requested subject matter experts and speaks at hundreds of conferences worldwide (when those used to exist) and webinars for the genomic, medical, oncologic, and patient advocate communities. He’s the James Bond – meets – Liam Neeson – meets Jason Bourne – meets – Austin Powers of all the things I just said. His key focus, which fascinates me, is understanding how factors like what country you’re born in, your socioeconomic status, and your genetic predispositions determine whether or not you enter the shit happens store of cancer. He’s also Canadian, but I forgive him. Although he does know Justin Trudeau, so I heard.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Optimal Duration of MRD Monitoring During Therapy for Childhood ALL
Minimal residual disease monitoring has been very helpful in early response evaluation and risk stratification of children with acute lymphoblastic leukemia (ALL). This podcast discusses the pros and cons of extended MRD monitoring throughout the duration of therapy for childhood ALL.